BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35412039)

  • 1. [Practical diagnostic aspects of uterine leiomyosarcoma in the context of the 2020 WHO classification].
    Horn LC; Hiller GGR; Mayr D; Schmoeckel E; Höhn AK
    Pathologe; 2022 May; 43(3):196-201. PubMed ID: 35412039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smooth muscle tumors of the uterus: a practical approach.
    Toledo G; Oliva E
    Arch Pathol Lab Med; 2008 Apr; 132(4):595-605. PubMed ID: 18384211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS).
    Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K
    Acta Obstet Gynecol Scand; 2004 Nov; 83(11):1085-8. PubMed ID: 15488127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoexpression of p53 in cutaneous and subcutaneous leiomyosarcomas.
    Fernandez-Flores A; Monteagudo C
    Ann Diagn Pathol; 2016 Oct; 24():25-9. PubMed ID: 27649950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
    Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
    Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital Quantification of Ki-67 and PHH3 in the Classification of Uterine Smooth Muscle Tumors.
    Cao CD; Rico-Castillo J; De Cotiis D; Richard SD; Rosenblum NG; Chan JSY
    Int J Gynecol Pathol; 2021 Nov; 40(6):549-555. PubMed ID: 33323861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraoperative Frozen Section Biopsy of Uterine Smooth Muscle Tumors: A Clinicopathologic Analysis of 112 Cases With Emphasis on Potential Diagnostic Pitfalls.
    Lok J; Tse KY; Lee EYP; Wong RWC; Cheng ISY; Chan ANH; Leung CKL; Cheung ANY; Ip PPC
    Am J Surg Pathol; 2021 Sep; 45(9):1179-1189. PubMed ID: 34074809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. POTENTIAL LIFE PROGNOSTIC MARKER FOR MESENCHYMAL TUMOR RESEMBLING UTERINE LEIOMYOSARCOMA.
    Nishikawa S; Hayashi T; Uzaki T; Yaegashi N; Abiko K; Konishi I
    Georgian Med News; 2023 Oct; (343):119-126. PubMed ID: 38096528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD147 expression in uterine smooth muscle tumors, and its potential role as a diagnostic and prognostic marker in patients with leiomyosarcoma.
    Ozler A; Evsen MS; Turgut A; Sak ME; Tunc SY; Agacayak E; Alabalik U; Basaranoglu S; Keles AN; Gul T
    J Exp Ther Oncol; 2014; 10(4):325-30. PubMed ID: 25509988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of counting positive PHH3 cells in the diagnosis of uterine smooth muscle tumors.
    Pang SJ; Li CC; Shen Y; Liu YZ; Shi YQ; Liu YX
    Int J Clin Exp Pathol; 2015; 8(5):4418-26. PubMed ID: 26191133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma.
    Baiocchi G; Poliseli FL; De Brot L; Mantoan H; Schiavon BN; Faloppa CC; Vassallo J; Soares FA; Cunha IW
    J Clin Pathol; 2016 Oct; 69(10):884-9. PubMed ID: 26994023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smooth Muscle Tumors of the Female Genital Tract.
    Devereaux KA; Schoolmeester JK
    Surg Pathol Clin; 2019 Jun; 12(2):397-455. PubMed ID: 31097110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential.
    Ip PP; Cheung AN
    Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):691-704. PubMed ID: 21865091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis in the diagnosis of uterine myometrial smooth muscle tumors.
    Stănescu AD; Nistor E; Sajin M; Stepan AE
    Rom J Morphol Embryol; 2014; 55(3 Suppl):1129-36. PubMed ID: 25607395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelioid Leiomyosarcoma of the Uterus: Modern Outcome-based Appraisal of Diagnostic Criteria in a Large Institutional Series.
    Chapel DB; Nucci MR; Quade BJ; Parra-Herran C
    Am J Surg Pathol; 2022 Apr; 46(4):464-475. PubMed ID: 34419987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.